{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:04:46Z","timestamp":1764828286547,"version":"build-2065373602"},"reference-count":34,"publisher":"Wiley","issue":"6P2","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":3517,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2002,6]]},"abstract":"<jats:p>Acute coronary syndromes encompass a spectrum of conditions, including myocardial infarction and unstable angina. These syndromes are related to the formation and disruption of atherosclerotic plaque. Rupture of plaque leads to thrombin generation, fibrin deposition, and platelet aggregation, ultimately resulting in restriction of blood flow and ischemia of cardiac tissue. Percutaneous coronary intervention (PCI), including angioplasty and coronary stent placement, has been developed to open occluded arteries. The frequency with which these procedures are performed speaks to their largely successful outcomes. However, the mechanical manipulations of PCI result in additional plaque rupture and damage to the vessel wall, exposing subendothelial components to blood and resulting in the initiation of the clotting cascade and in platelet activation. Left unchecked, these intertwined processes lead to formation of arterial thrombi at the site of endothelial damage, and potentially to abrupt vessel closure or embolization of thrombi into the distal microcirculation. Thrombin plays a central role in thrombus formation and platelet activation, and its inhibition significantly reduces thrombus\u2010related sequelae. Current antithrombotic strategies during PCI are based on the traditional indirect thrombin inhibitor heparin. Heparin has several limitations in efficacy and safety, due in part to its indirect mechanism of action. Bivalirudin, a direct thrombin inhibitor, offers significant improvement over heparin in the clinical outcomes and risks associated with PCI.<\/jats:p>","DOI":"10.1592\/phco.22.10.97s.33614","type":"journal-article","created":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T07:05:12Z","timestamp":1086073512000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Role of Thrombin Inhibition During Percutaneous Coronary Intervention"],"prefix":"10.1002","volume":"22","author":[{"given":"Ann K.","family":"Wittkowsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199201233260406"},{"key":"e_1_2_1_3_2","first-page":"743","volume-title":"Hemostasis and thrombosis: basic principles and clinical practice","author":"Libby P.","year":"2000"},{"key":"e_1_2_1_4_2","first-page":"3","volume-title":"Hemostasis and thrombosis: basic principles and clinical practice","author":"Colman R.","year":"2000"},{"key":"e_1_2_1_5_2","first-page":"171","volume-title":"Hemostasis and thrombosis: basic principles and clinical practice","author":"Jenny N.","year":"2000"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/35025229"},{"key":"e_1_2_1_7_2","first-page":"233","volume-title":"Hemostasis and thrombosis: basic principles and clinical practice","author":"Loewy A.G.","year":"2000"},{"key":"e_1_2_1_8_2","first-page":"37F","article-title":"Cost analysis of bivalirudin in percutaneous coronary intervention","volume":"12","author":"Lauer M.A.","year":"2000","journal-title":"J Invasive Cardiol"},{"volume-title":"Heart and stroke statistical update","year":"2001","author":"American Heart Association.","key":"e_1_2_1_9_2"},{"issue":"3","key":"e_1_2_1_10_2","first-page":"5","article-title":"Production and chemical processing of low\u2010molecular\u2010weight heparins","volume":"25","author":"Linhardt R.J.","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.1_suppl.64S"},{"key":"e_1_2_1_12_2","first-page":"27F","article-title":"The mechanism of action of thrombin inhibitors","volume":"12","author":"Bates S.M.","year":"2000","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.3.251"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(00)90050-4"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.7.1929"},{"key":"e_1_2_1_16_2","first-page":"300","article-title":"Of anticoagulant and antiplatelet therapy in percutaneous coronary intervention","volume":"6","author":"Bell D.","year":"2001","journal-title":"J Inform Pharmacother"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.5858\/2000-124-1657-POHIT","article-title":"Pathophysiology of heparin\u2010induced thrombocytopenia. Clinical and diagnostic implications\u2014a review","volume":"124","author":"Fabris F.","year":"2000","journal-title":"Arch Pathol Lab Med"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-136-3-200202050-00009"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708143370702"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.15.1593"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103013440901"},{"issue":"2","key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1093\/ajhp\/58.suppl_2.S14","article-title":"Fondaparinux sodium: a selective inhibitor of factor Xa","volume":"58","author":"Bauer K.A.","year":"2001","journal-title":"Am J Health-Syst Pharm"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.114.5_Supplement.715S"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.87.5.1622"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809202601211"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.13.1123.35039"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10301"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.4.318.34881"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07495-0"},{"key":"e_1_2_1_30_2","first-page":"829","article-title":"Comparison of antithrombotic activities of heparin and hirulog\u20101: basis for improved antithrombotic properties of direct thrombin inhibitors [abstr]","volume":"65","author":"Maraganore J.M.","year":"1991","journal-title":"Thromb Haemost"},{"issue":"5","key":"e_1_2_1_31_2","article-title":"The thrombin\u2010specific anticoagulant, \u03b1 bivalirudin, completely inhibits thrombin\u2010mediated platelet aggregation [abstr]","volume":"88","author":"Weitz J.","year":"2001","journal-title":"Am J Cardiol"},{"key":"e_1_2_1_32_2","first-page":"33F","article-title":"The use of bivalirudin in patients with renal impairment","volume":"12","author":"Robson R.","year":"2000","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_1_33_2","first-page":"41F","article-title":"Dosage, pharmacological effects and clinical outcomes for bivalirudin in percutaneous coronary intervention","volume":"12","author":"Lui H.K.","year":"2000","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2001.119374"},{"key":"e_1_2_1_35_2","first-page":"813","article-title":"Switching from heparin to a thrombin\u2010specific anticoagulant (bivalirudin) for percutaneous transluminal coronary angioplasty in unstable angina patients reduces major clinical events [abstr]","volume":"102","author":"Bittl J.A.","year":"2000","journal-title":"Circulation"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.22.10.97S.33614","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.22.10.97S.33614","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:47:39Z","timestamp":1761068859000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.22.10.97S.33614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6]]},"references-count":34,"journal-issue":{"issue":"6P2","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["10.1592\/phco.22.10.97S.33614"],"URL":"https:\/\/doi.org\/10.1592\/phco.22.10.97s.33614","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2002,6]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}